Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shi Li

Showing results (1131-1140 of 1,141) with videos related to

Pageof 115
Sort By:
Plos One|October 23, 2013
Mosquitoes of Western Yunnan Province, China: seasonal abundance, diversity, and arbovirus associationsHai-Lin Zhang, Yu-Zhen Zhang, Wei-Hong Yang, et al.
Free Radical Biology & Medicine|May 21, 2026
ALDH2 alleviates diabetes-induced myocardial cell senescence and electrical remodeling by regulating SIRT1Lei Wang, Hui-Hui Wang, Qing Chen, et al.
CA: a Cancer Journal for Clinicians|March 12, 2026
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 studyJian-Chun Duan, Jia Zhong, Bo-Yang Sun, et al.
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
Neuron|October 13, 2021
TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's diseaseBo Am Seo, Donghoon Kim, Heehong Hwang, et al.
Contemporary Clinical Trials Communications|June 12, 2025
SHengXIaN-QuYu DEcoction in the Treatment of Heart Failure with Reduced and Mildly-Reduced Ejection Fraction (SHINE-HF): rationale and design for a multicenter randomized controlled trialLina Feng, Sizhen Chen, Jiang Liu, et al.
Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
NPJ Vaccines|March 19, 2023
Evaluation of the immunization effectiveness of bOPV booster immunization and IPV revaccinationZhao Yu-Ping, Li Jing, Huang Teng, et al.
International Journal of Radiation Oncology, Biology, Physics|July 15, 2024
International Recommendations on Postoperative Management for Potentially Resectable Locally Recurrent Nasopharyngeal CarcinomaJi-Shi Li, Pierre Blanchard, Charlene H L Wong, et al.
Kidney International|July 3, 2009
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility, Ian S D Roberts, H Terence Cook, et al.
Pageof 115

Showing results (1131-1140 of 1,141) with videos related to

Sort By:
Pageof 115
Plos One|October 23, 2013
Mosquitoes of Western Yunnan Province, China: seasonal abundance, diversity, and arbovirus associationsHai-Lin Zhang, Yu-Zhen Zhang, Wei-Hong Yang, et al.
Free Radical Biology & Medicine|May 21, 2026
ALDH2 alleviates diabetes-induced myocardial cell senescence and electrical remodeling by regulating SIRT1Lei Wang, Hui-Hui Wang, Qing Chen, et al.
CA: a Cancer Journal for Clinicians|March 12, 2026
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 studyJian-Chun Duan, Jia Zhong, Bo-Yang Sun, et al.
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
Neuron|October 13, 2021
TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's diseaseBo Am Seo, Donghoon Kim, Heehong Hwang, et al.
Contemporary Clinical Trials Communications|June 12, 2025
SHengXIaN-QuYu DEcoction in the Treatment of Heart Failure with Reduced and Mildly-Reduced Ejection Fraction (SHINE-HF): rationale and design for a multicenter randomized controlled trialLina Feng, Sizhen Chen, Jiang Liu, et al.
Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
NPJ Vaccines|March 19, 2023
Evaluation of the immunization effectiveness of bOPV booster immunization and IPV revaccinationZhao Yu-Ping, Li Jing, Huang Teng, et al.
International Journal of Radiation Oncology, Biology, Physics|July 15, 2024
International Recommendations on Postoperative Management for Potentially Resectable Locally Recurrent Nasopharyngeal CarcinomaJi-Shi Li, Pierre Blanchard, Charlene H L Wong, et al.
Kidney International|July 3, 2009
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility, Ian S D Roberts, H Terence Cook, et al.
Pageof 115